Analyst Price Target is $64.50
▲ +39.94% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Simulations Plus in the last 3 months. The average price target is $64.50, with a high forecast of $76.00 and a low forecast of $53.00. The average price target represents a 39.94% upside from the last price of $46.09.
Current Consensus is
The current consensus among 4 polled investment analysts is to buy stock in Simulations Plus. This rating has held steady since September 2020, when it changed from a Hold consensus rating.
Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. It operates through the following segments: Simulations Plus, Inc., Cognigen Corporation, DILIsym, and Lixoft. It designs and develops pharmaceutical simulation software to promote cost-effective solutions to a number of problems in pharmaceutical research and in the education of pharmacy and medical students. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered in Lancaster, CA.